Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study

NCT00182052 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00182052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00182052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2000
Completion date
August 31, 2003
Enrollment
100 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, prostate cancer